Analysts expect Biomerica, Inc. (NASDAQ:BMRA) to post earnings per share (EPS) of ($0.05) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Biomerica’s earnings. Biomerica posted earnings of ($0.04) per share during the same quarter last year, which suggests a negative year over year growth rate of 25%. The business is expected to issue its next earnings report on Monday, April 15th.

On average, analysts expect that Biomerica will report full year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.20). For the next fiscal year, analysts forecast that the firm will post earnings of ($0.32) per share, with EPS estimates ranging from ($0.36) to ($0.27). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Biomerica.

Biomerica (NASDAQ:BMRA) last issued its earnings results on Tuesday, January 15th. The company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Biomerica had a negative net margin of 36.36% and a negative return on equity of 45.72%. The firm had revenue of $1.50 million during the quarter, compared to the consensus estimate of $1.51 million.

Separately, B. Riley lowered their target price on shares of Biomerica from $7.50 to $6.25 and set a “buy” rating for the company in a research note on Monday, December 17th.

Shares of NASDAQ:BMRA opened at $2.55 on Monday. Biomerica has a 52 week low of $1.60 and a 52 week high of $4.33. The company has a market capitalization of $23.41 million, a price-to-earnings ratio of -15.00 and a beta of 1.36.

An institutional investor recently bought a new position in Biomerica stock. Perritt Capital Management Inc. purchased a new stake in Biomerica, Inc. (NASDAQ:BMRA) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 40,000 shares of the company’s stock, valued at approximately $68,000. Perritt Capital Management Inc. owned 0.43% of Biomerica as of its most recent SEC filing. 0.94% of the stock is currently owned by institutional investors.

Biomerica Company Profile

Biomerica, Inc, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The company's diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.

Featured Story: How Do You Calculate Return on Investment (ROI)?

Get a free copy of the Zacks research report on Biomerica (BMRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with's FREE daily email newsletter.